Tirzepatide 40mg

Overview

Tirzepatide is a synthetic dual agonist peptide designed for research into glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor biology. As a unimolecular synthetic peptide with modifications enabling both receptor activation and extended pharmacokinetics, Tirzepatide serves as an experimental tool for investigating incretin-based metabolic regulation, energy homeostasis, and cardiorenal physiology in controlled laboratory settings.

In experimental biology, Tirzepatide is utilized to explore synergistic mechanisms of dual incretin receptor co-activation across multiple organ systems. By simultaneously engaging GIP and GLP-1 receptor signaling pathways — targeting pancreatic beta-cell function, central appetite circuits, gastric motility, adipose metabolism, and vascular protection endpoints — this peptide enables comprehensive study of metabolic disease mechanisms, glycemic regulation, body composition dynamics, and tissue-specific insulin sensitivity in preclinical research models.

Biochemical Characteristics

• Peptide Name: Tirzepatide
• Structure: 39-amino acid synthetic peptide based on native GIP sequence with site-specific modifications
• Molecular Formula: C₂₂₅H₃₄₈N₄₈O₆₈
• Molecular Weight: ~4,813 Da (unmodified peptide backbone)

Structural Modifications:

• C20 fatty diacid acyl chain (icosanedioic acid) conjugated via γ-glutamic acid-based linker at position 20 (Lys residue)
• Two amino acid substitutions (Ala²→Aib, Ser¹³→α-methylserine) to enhance receptor selectivity and proteolytic resistance

Receptor Binding Profile:

• GIP Receptor (GIPR): Near-native agonist potency
• GLP-1 Receptor (GLP-1R): ~20% potency relative to native GLP-1
• In vitro GIPR:GLP-1R potency ratio: ~5:1

Pharmacokinetic Characteristics (Preclinical):

• Half-Life: ~5 days in preclinical models (attributed to albumin binding via fatty acid chain and DPP-4 resistance)
• Formulation: Lyophilized powder; reconstituted solution stable under refrigeration

Research Applications

Tirzepatide is employed exclusively within laboratory research workflows to model and investigate dual incretin receptor biology. Common experimental applications include:

Metabolic & Endocrine Research

• Glucose Homeostasis Models — Investigating glucose-dependent insulin secretion, beta-cell proliferation, and alpha-cell glucagon suppression pathway dynamics in controlled diabetes research models
• Energy Balance Studies — Evaluating energy expenditure endpoints, adipose tissue remodeling markers including browning and lipolytic signaling
• Body Composition Research — Assessing dose-dependent body composition kinetics and lean mass preservation endpoints in preclinical models

Cardiovascular & Renal Biology

• Cardiorenal Endpoint Modeling — Studying albuminuria markers, endothelial function parameters, blood pressure regulation endpoints, and vascular inflammation indicators in metabolic disease models
• Atherosclerosis Research Models — Examining lipid metabolism pathway activity, macrophage polarization dynamics, and plaque-associated molecular markers

Hepatic & Adipose Tissue Research

• MASLD/NASH Models — Investigating hepatic steatosis markers, fibrosis-associated endpoints, and liver enzyme normalization in controlled experimental systems
• Adipocyte Biology — Exploring adipogenesis pathway activity, insulin sensitivity markers, and inflammatory cytokine release profiles

Gastrointestinal & Neural Signaling

• Gastric Motility Studies — Characterizing gastric emptying dynamics and nutrient absorption kinetics under defined experimental conditions
• Central Appetite Circuit Research — Mapping hypothalamic and brainstem neural circuit activation including POMC/CART and NPY/AgRP pathway endpoints

Incretin Pathway Synergy Research

• Comparative studies versus selective GLP-1 agonists to elucidate additive and synergistic mechanistic effects of dual GIPR/GLP-1R activation in preclinical systems

Pathway & Mechanistic Context

Research documents Tirzepatide's dual receptor agonism across overlapping and complementary signaling networks:

Incretin Signaling Cascades

• GIP Receptor Activation — Examined for glucose-dependent insulin secretion enhancement, adipocyte lipid storage dynamics under nutrient-replete conditions, and beta-cell survival pathway activity via PKA and Epac signaling
• GLP-1 Receptor Activation — Studied for insulin release stimulation, glucagon secretion suppression, gastric emptying modulation, and central satiety circuit activation including arcuate nucleus and nucleus tractus solitarius pathway endpoints

Synergistic Metabolic Pathway Modeling

Combined GIPR/GLP-1R activation in preclinical models demonstrates superior glycemic regulation and body composition endpoint changes compared to selective GLP-1 agonism alone. GIP receptor activity may modulate GLP-1-mediated lipolytic signaling in certain experimental contexts while supporting insulin sensitivity and glucose disposal pathway activity.

Downstream Signaling Pathways

• cAMP/PKA/CREB — Both receptors couple to Gαs, triggering cyclic AMP production and downstream transcriptional activity
• PI3K/Akt — Mediates beta-cell proliferation, survival signaling, and peripheral glucose uptake pathway activity
• mTOR & AMPK Modulation — Regulates cellular energy sensing and metabolic substrate utilization endpoints

Tissue-Specific Research Endpoints

• Pancreas — Glucose-dependent insulin secretion, beta-cell proliferation markers, apoptosis-related endpoints
• Brain — Anorexigenic signaling pathway activity, neuroprotection markers, reward pathway modulation
• Liver — Gluconeogenesis pathway markers, hepatic insulin sensitivity endpoints, lipid accumulation indicators
• Adipose Tissue — Insulin sensitivity markers, white adipose tissue browning endpoints, inflammatory tone indicators
• Kidney — Glomerular hyperfiltration markers, albuminuria endpoints, renal hemodynamic parameters

Preclinical Research Summary

1. Glycemic Regulation Research
Rodent and non-human primate models document dose-dependent changes in fasting glucose, postprandial glucose excursion endpoints, and HbA1c-equivalent markers under defined experimental conditions.

2. Body Composition & Energy Metabolism Studies
Preclinical diet-induced obesity models evaluate fat mass reduction endpoints, lean body mass preservation markers, and energy expenditure dynamics. Enhanced thermogenesis parameters have been documented via indirect calorimetry in controlled research settings.

3. Cardiometabolic Endpoint Research
Preclinical studies report lipid profile endpoint changes including triglyceride and LDL-C markers, systemic inflammation indicators including IL-6, TNF-α, and CRP-associated markers, and cardioprotective endpoints in ischemia-reperfusion injury research models.

4. Hepatic Research Models
Controlled laboratory studies document liver fat content markers, histological scoring endpoints in NASH research models, and hepatocellular injury markers including ALT and AST normalization as experimental readouts.

Form & Analytical Testing

Tirzepatide is supplied as a sterile lyophilized powder manufactured via solid-phase peptide synthesis (SPPS) with subsequent lipidation and purification steps to achieve the final acylated research compound structure.

Quality control verification includes:

• HPLC & MS/MS — Identity confirmation and sequence integrity verification
• Analytical HPLC — Purity assessment
• Endotoxin Testing — <1.0 EU/mg
• Sterility Verification — Compliant with USP <71> standards for research-grade materials

Purity & Quality

• ≥99% Purity — HPLC Verified
• Independently tested by accredited third-party laboratory
• Certificate of Analysis (CoA) available for every batch documenting molecular weight, purity, sequence integrity, and storage recommendations

Research Use Only (RUO) Notice

All products are furnished strictly for in-vitro laboratory research use only. "In-vitro" refers to studies conducted outside of a living organism under controlled experimental conditions. These materials are not pharmaceuticals, drugs, or therapeutic agents and have not been evaluated or approved by the U.S. Food and Drug Administration (FDA) to diagnose, treat, cure, or prevent any disease or medical condition. Tirzepatide is intended exclusively for use by qualified researchers in academic, biotechnology, or pharmaceutical research settings. Introduction into humans or animals is strictly prohibited. Not for human, medical, diagnostic, or veterinary use.

All Tirzepatide research compounds supplied by P1 Peptides are produced using lyophilization — also known as freeze-drying or cryodesiccation — a specialized dehydration process widely employed in the manufacture of research-grade synthetic peptide materials.

During this process, the peptide solution is first frozen to subzero temperatures and then subjected to low vacuum pressure conditions, allowing frozen water content to sublimate directly from solid ice to vapor phase, bypassing the liquid phase entirely. The result is a dry, porous crystalline powder — commonly referred to as a lyophilized peptide cake — that retains full structural integrity while remaining shelf-stable under controlled storage conditions.

In its lyophilized form, Tirzepatide remains stable for up to 12–18 months when stored properly under recommended conditions prior to reconstitution.

Reconstitution

When research protocols require reconstitution, Tirzepatide is typically prepared using bacteriostatic water (0.9% benzyl alcohol) under controlled laboratory conditions. Once reconstituted, the peptide solution must be refrigerated at 2–8°C (36–46°F) to maintain compound stability. Reconstituted solutions are generally stable for up to 28–30 days when stored appropriately under refrigeration.

To preserve structural integrity of the reconstituted solution, researchers should avoid exposure to direct light and minimize temperature fluctuations throughout the storage period. Reconstituted solutions displaying cloudiness, discoloration, or particulate matter should be discarded. Do not freeze reconstituted Tirzepatide solutions.

All reconstitution procedures should be carried out in accordance with standard laboratory protocols applicable to synthetic peptide research materials.

Recommended Storage Guidelines

The following storage parameters are recommended to maintain compound integrity throughout the research lifecycle:

Short-Term Storage — Unopened Lyophilized Vials

• Upon Receipt — Store unopened vials under refrigeration at 2–8°C (36–46°F), protected from direct light
• Lyophilized Tirzepatide may tolerate brief ambient temperature exposure during transit; however prolonged storage above 8°C is not recommended to preserve maximum compound integrity
• Under refrigerated conditions, lyophilized vials remain stable for several months

Long-Term Storage — Unopened Lyophilized Vials

• Extended Storage (6–18 months or longer) — Freezing at −20°C (−4°F) or below is recommended
• Optimal Long-Term Preservation — Storage at −80°C (−112°F) provides maximum stability, minimizing peptide degradation, aggregation, and oxidative modification over extended periods
• Repeated freeze-thaw cycles should be avoided, as temperature cycling may compromise structural integrity of the compound

Post-Reconstitution Storage

• Store reconstituted solutions upright under refrigeration at 2–8°C (36–46°F), away from direct light
• Do not freeze reconstituted solutions
• Discard any unused reconstituted material after 30 days or upon observation of cloudiness, discoloration, or particulate matter

Additional Laboratory Guidance

For specific storage requirements applicable to this research compound, researchers should consult the Certificate of Analysis (CoA) provided with each batch, as well as applicable peer-reviewed literature and institutional laboratory protocols governing synthetic peptide handling and storage procedures.

Research Use Only (RUO) Notice

All products are furnished strictly for in-vitro laboratory research use only. These materials are not medicines or drugs and have not been evaluated or approved by the U.S. Food and Drug Administration (FDA) to diagnose, treat, cure, or prevent any disease or medical condition. Introduction into humans or animals is strictly prohibited. Not for human, medical, diagnostic, or veterinary use.